32. traDe anD other payaBles The breakdown of trade and other payables is as follows: The Group lost control of a subsidiary as a result of disposal of the Group’s investment for the year ended 31 March 2014. The total  consideration received in respect of sales of the subsidiary, and the breakdown of assets and liabilities of the subsidiary transferred  are as follows: Total consideration received: ¥22,963 million Breakdown of assets and liabilities of subsidiary transferred 33. cash flow inforMation (Millions of yen) 1 April 2012  (Transition date) 2013 2014 Account payables—trade ¥108,401 ¥102,835 ¥102,025 Other payables 102,488 103,797 85,071 Total trade and other payables ¥210,888 ¥206,631 ¥187,096 Non-current ¥ 11,625 ¥ 4,869 ¥ 64 Current 199,263 201,762 187,032 (Millions of yen) Assets Property, plant and equipment ¥15,929 Other assets 815 Cash and cash equivalents 4,371 Total assets ¥21,115 Liabilities Other financial liabilities (non-current) ¥ 2,402 Other liabilities 439 Total liabilities ¥ 2,841 The Group monitors financial indicators in order to maintain  an optimal capital structure. Credit ratings are monitored for  financial soundness and flexibility, and so is return on equity  attributable to owners of the parent (ROE) for capital efficiency. The Group is not subject to material capital regulation. The Group’s capital management principle is to maintain an  optimal capital structure by improving capital efficiency and  ensuring sound and flexible financial conditions in order to  achieve sustained improvement in the enterprise value, which  will lead to improved return to shareholders. 34. financial instruMents (1) Capital management Astellas Pharma Inc.  _ Annual Report 2014 140